Document is current
Any future updates will be listed below
-
Authors
Pigazzi, Martina https://orcid.org/0000-0002-4793-5263
Merlini, Silvia
Da Ros, Ambra
Marini, Olivia https://orcid.org/0000-0002-0196-3445
Faggin, Giovanni https://orcid.org/0000-0002-5443-5638
Fortuna, Nicolò
Mattera, Raffaele
Buldini, Barbara
Rizzardi, Paolo https://orcid.org/0009-0008-8141-7305
Meshinchi, Soheil https://orcid.org/0000-0002-6276-4423
Basso, Giuseppe https://orcid.org/0000-0002-2634-9302
Locatelli, Franco https://orcid.org/0000-0002-7976-3654
Biffi, Alessandra https://orcid.org/0000-0002-4610-0870
-
Funding
Funding for this research was provided by:
Fondazione Città della Speranza (IRP-synergy grant)
Fondazione Città della Speranza (IRP-synergy)
Associazione Italiana per la Ricerca sul Cancro (IG-20562)
Ministero dell'Istruzione, dell'Università e della Ricerca (PNRR CN3-National Center for Gene Therapy and Drugs Based on RNA Technology)
Ministero dell'Istruzione, dell'Università e della Ricerca (PNRR CN3-National Center for Gene Therapy and Drugs Based on RNA Technology)
Altheia science
- License Information
-
More Information
Article History
Received: 12 April 2025
Accepted: 1 April 2026
First Online: 8 May 2026
Competing interests
: A.B. and M.P. are inventors on the following patent applications: PCT/EP2022/059031 and PCT/EP2023/059054. Alhena Science owns the rights to its exploitation. P.R. is an employee of Alhena Science. A.B. and M.P. are scientific advisors for Alhena Science; A.B. and M.P. are shareholders of the company. The remaining authors declare no competing interests.
